Khawar et al. published a paper indicating that the pharmacokinetics of [44Sc]Sc-PSMA-617-based (PSMA (prostate-specific membrane antigen)) PET/CT imaging serves as a useful tool for the calculation of normal organ-absorbed doses and the maximum allowable activity in prostate-cancer patients prior to lutetium-177 (177Lu)-labelled PSMA-617 ([177Lu]Lu-PSMA-617) radiotherapy [36]. Here, FOLH1 is linked to prostate carcinoma.